Proton pump inhibitors vs h2 blockers
Pro Research Analysisby 
Searched over 200M research papers
Comparative Effectiveness: Proton Pump Inhibitors vs H2 Blockers for Acid Suppression
Efficacy in Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease
Proton pump inhibitors (PPIs) are generally more effective than H2 receptor blockers (H2RBs) in relieving symptoms and healing esophageal lesions in patients with GERD. Studies show that PPIs provide higher rates of symptom resolution (78% vs 54%) and esophageal healing (84% vs 62%) compared to H2RBs, with faster relief of symptoms as well (average 5 days for PPIs vs 8 days for H2RBs) Khan2024Freston1993. Both drug classes are well-tolerated, with similar rates of mild side effects .
Stress Ulcer Prophylaxis in Critically Ill and Cardiovascular Patients
In ICU patients requiring mechanical ventilation, PPIs and H2RBs show similar in-hospital mortality rates (18.3% for PPIs vs 17.5% for H2RBs), with PPIs slightly reducing the risk of clinically important upper gastrointestinal bleeding (1.3% vs 1.8%) . However, in ICU patients hospitalized for major adverse cardiovascular and cerebrovascular events, PPI use is associated with higher 90-day mortality compared to H2RBs (27% vs 19.5%) . Some evidence suggests that drug interactions between PPIs and antiplatelet agents may contribute to worse cardiovascular outcomes, leading to renewed interest in H2RBs for these patients .
Long-Term Mortality and Safety Concerns
Large cohort studies in US veterans indicate that long-term PPI use is associated with increased all-cause and some cause-specific mortality compared to H2RBs, including higher risks of death from circulatory system diseases, cancer, and kidney-related conditions Koretz2019Xie2017. The risk appears to increase with longer duration of PPI use, and is present even in patients without gastrointestinal conditions . However, some studies caution that these findings are observational and may be influenced by confounding factors .
Renal Outcomes: Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD)
Research shows that PPI use is linked to a higher risk of developing CKD, progression of CKD, and ESRD compared to H2RBs . However, in patients with established CKD, PPI use does not appear to increase the risk of mortality or progression to ESRD compared to H2RBs or no acid-suppressing therapy .
Combination Therapy and Special Considerations
For GERD patients experiencing nocturnal acid breakthrough while on PPIs, adding a bedtime H2 blocker can improve nighttime acid control . In cases of refractory reflux esophagitis, PPIs are more effective than H2RBs, especially when H2RBs have failed .
Conclusion
PPIs are more effective than H2 blockers for symptom relief and healing in GERD and peptic ulcer disease, and may offer better protection against upper GI bleeding in critically ill patients. However, H2 blockers may be safer in patients with cardiovascular disease or those at risk for long-term adverse effects, including mortality and kidney disease. The choice between PPIs and H2 blockers should be individualized, considering both efficacy and patient-specific risk factors Young2020Pu2024Koretz2019+6 MORE.
Sources and full results
Most relevant research papers on this topic